Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal

Pharmacological Research

Volumn 51, Issue 1, 2005, Pages 69-78

  Grasing, Kenneth ^a,b   He, Shaunteng ^a   Li, Ning ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Dependence syndrome; Morphine; Reinforcement; Selegiline; Self administration; Withdrawal

Indexed keywords

MORPHINE; SELEGILINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; LATENT PERIOD; LOCOMOTION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALS; CUES; EXTINCTION, PSYCHOLOGICAL; MALE; MORPHINE; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SELEGILINE; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 7044233727     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.07.004     Document Type: Article

References (59)

1. M.B. Youdim, A. Gross, and J.P. Finberg Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br J Pharmacol 132 2001 500 506
2. P.C. Waldmeier, and A.E. Felner Deprenil, loss of selectivity for inhibition of b-type MAO after repeated treatment Biochem Pharmacol 27 1978 801 806
3. W.P. Melega, A.K. Cho, D. Schmitz, R. Kuczenski, and D.S. Segal l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine J Pharmacol Exp Ther 288 1999 752 758
4. K.S. Ansari, P.H. Yu, T.P. Kruck, and W.G. Tatton Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition J Neurosci 13 1993 4042 4053
5. J.S. Wadia, R.M. Chalmers-Redman, W.J. Ju, G.W. Carlile, J.L. Phillips, and A.D. Fraser Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl J Neurosci 18 1998 932 947
6. K. Puurunen, J. Jolkkonen, J. Sirvio, A. Haapalinna, and J. Sivenius Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats Exp Neurol 167 2001 348 355
7. T.R. Kosten, T.P. George, and T.A. Kosten The potential of dopamine agonists in drug addiction Expert Opin Investig Drugs 11 2002 491 499
8. T.P. George, J.C. Vessicchio, A. Termine, P.I. Jatlow, T.R. Kosten, and S.S. O'Malley A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation Biol Psychiatr 53 2003 136 143
9. N.D. Volkow, J.S. Fowler, and G.J. Wang Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies Behav Pharmacol 13 2002 355 366
10. G. Di Chiara, and A. Imperato Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats Proc Natl Acad Sci USA 85 1988 5274 5278
11. E. Acquas, and G. Di Chiara Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence J Neurochem 58 1992 1620 1625
12. M. Diana, A.L. Muntoni, M. Pistis, M. Melis, and G.L. Gessa Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal Eur J Neurosci 11 1999 1037 1041
13. G. Engberg, T. Elebring, and H. Nissbrandt Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites: effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons J Pharmacol Exp Ther 259 1991 841 847
14. N.B. Mercuri, M. Scarponi, A. Bonci, A. Siniscalchi, and G. Bernardi Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells J Neurosci 17 1997 2267 2272
15. S. Ghosh, and K. Grasing Presynaptic dopaminergic function in the nucleus accumbens following chronic opiate treatment and precipitated withdrawal Neurochem Res 24 1999 95 107
16. K. Grasing, and S. Ghosh Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal Neuropharmacology 37 1998 1007 1017
17. D.M. Hutcheson, B.J. Everitt, T.W. Robbins, and A. Dickinson The role of withdrawal in heroin addiction: enhances reward or promotes avoidance? Nat Neurosci 4 2001 943 947
18. M. Navarro, J.J. Fernandez-Ruiz, F. Rodriguez de Fonseca, M.L. Hernandez, M. Cebeira, and J.A. Ramos Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice Pharmacol Biochem Behav 43 1992 603 608
19. G.J. Wang, N.D. Volkow, J.S. Fowler, J. Logan, N.N. Abumrad, and R.J. Hitzemann Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal Neuropsychopharmacology 16 1997 174 182
20. M. Ary, B. Cox, and P. Lomax Dopaminergic mechanisms in precipitated withdrawal in morphine-dependent rats J Pharmacol Exp Ther 200 1977 271 276
21. C.L. Walters, G. Aston-Jones, and J.P. Druhan Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist Neuropsychopharmacology 23 2000 307 315
22. S. He, N. Li, and K. Grasing Long-term opiate effects on amphetamine-induced dopamine release in the nucleus accumbens core and conditioned place preference Pharmacol Biochem Behav 77 2004 327 335
23. He S, Grasing K. Chronic opiate treatment enhances both cocaine-reinforced and cocaine-seeking behaviors following opiate withdrawal. Drug Alcohol Depend, in press.
24. E.H. Heinonen, M.I. Anttila, and R.A. Lammintausta Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites Clin Pharmacol Ther 56 1994 742 749
25. A.E. Felner, and P.C. Waldmeier Cumulative effects of irreversible MAO inhibitors in vivo Biochem Pharmacol 28 1979 995 1002
26. S.B. Caine, R. Lintz, and G.F. Koob Intravenous drug self-administration techniques in animals A. Sahgal Behavioral Neuroscience: A Practical Approach 1993 Oxford University Press Oxford 117 143
27. D. Stafford, M.G. LeSage, and J.R. Glowa Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review Psychopharmacology 139 1998 169 184
28. K. Grasing, N. Li, S. He, C. Parrish, J. Delich, and J. Glowa A new progressive ratio schedule for support of morphine self-administration in opiate dependent rats Psychopharmacology 168 2003 387 396
29. N. Li, S. He, C. Parrish, J. Delich, and K. Grasing Differences in morphine and cocaine reinforcement under fixed and progressive ratio schedules: effects of extinction, reacquisition and schedule design Behav Pharmacol 14 2003 619 630
30. C. Colantuoni, P. Rada, J. McCarthy, C. Patten, N.M. Avena, and A. Chadeayne Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence Obes Res 10 2002 478 488
31. J.L. Cao, H.L. Ding, L.C. Zhang, S.M. Duan, and Y.M. Zeng Pretreatment with midazolam suppresses morphine withdrawal response in mice and rats Acta Pharmacol Sin 23 2002 685 690
32. H.N. Bhargava, and E.L. Way Morphine tolerance and physical dependence: influence of cholinergic agonists and antagonists Eur J Pharmacol 36 1976 79 88
33. V.F. Gellert, and S.G. Holtzman Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions J Pharmacol Exp Ther 205 1978 536 546
34. J. Knoll, and I. Miklya Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition Arch Int Pharmacodyn Ther 328 1994 1 15
35. W.K. Schiffer, M. Azmoodeh, M. Gerasimov, N.D. Volkow, J.S. Fowler, and S.L. Dewey Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine Synapse 48 2003 35 38
36. I. Lamensdorf, M.B. Youdim, and J.P. Finberg Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo J Neurochem 67 1996 1532 1539
37. J. Fang, and P.H. Yu Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake Neuropharmacology 33 1994 763 768
38. M.D. Berry, A.V. Juorio, and I.A. Paterson The functional role of monoamine oxidases A and B in the mammalian central nervous system Prog Neurobiol 42 1994 375 391
39. W. Maruyama, Y. Akao, M.C. Carrillo, K. Kitani, M.B. Youdium, and M. Naoi Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes Neurotoxicol Teratol 24 2002 675 682
40. M.C. Carrillo, S. Kanai, Y. Sato, M. Nokubo, G.O. Ivy, and K. Kitani The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats Life Sci 52 1993 1925 1934
41. K.D. Dougherty, T.J. Walsh, S. Bailey, S. Schlussman, and K. Grasing Acquisition of a morris water maze task is impaired during early but not late withdrawal from morphine Pharmacol Biochem Behav 55 1996 227 235
42. A. Bechara, K. Nader, and D. van der Kooy A two-separate-motivational- systems hypothesis of opioid addiction Pharmacol Biochem Behav 59 1998 1 17
43. T.J. De Vries, A.N. Schoffelmeer, R. Binnekade, H. Raaso, and L.J. Vanderschuren Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization Neuropsychopharmacology 26 2002 18 26
44. T.J. De Vries, A.N. Schoffelmeer, R. Binnekade, and L.J. Vanderschuren Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration Psychopharmacology 143 1999 254 260
45. A. Bonci, G. Bernardi, P. Grillner, and N.B. Mercuri The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 24 2003 172 177
46. D. O'Regan, R.P. Kwok, P.H. Yu, B.A. Bailey, A.J. Greenshaw, and A.A. Boulton A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition Psychopharmacology 92 1987 42 47
47. G.D. Winger, S. Yasar, S.S. Negus, and S.R. Goldberg Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys Clin Pharmacol Ther 56 1994 774 780
48. S. Yasar, J.P. Goldberg, and S.R. Goldberg Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research J Neural Transm Suppl 48 1996 61 73
49. I.A. Paterson, A.J. Barber, D.L. Gelowitz, and C. Voll (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells Neurosci Biobehav Rev 21 1997 181 186
50. L.G. Chia, S.P. Liu, and E.H. Lee Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice Neuroreport 3 1992 777 780
51. E.J. Houtsmuller, J.A. Thornton, and M.L. Stitzer Effects of selegiline (l-deprenyl) during smoking and short-term abstinence Psychopharmacology 163 2002 213 320
52. A. Markou, T.R. Kosten, and G.F. Koob Neurobiological similarities in depression and drug dependence: a self-medication hypothesis Neuropsychopharmacology 18 1998 135 174
53. R.D. Porsolt, A. Bertin, N. Blavet, M. Deniel, and M. Jalfre Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity Eur J Pharm 57 1979 201 210
54. G.C. Harris, K. Altomare, and G. Aston-Jones Preference for a cocaine-associated environment is attenuated by augmented accumbal serotonin in cocaine withdrawn rats Psychopharmacology 156 2001 14 22
55. M.N. Gordon, C.D. Muller, K.A. Sherman, D.G. Morgan, A.J. Azzaro, and L. Wecker Oral versus transdermal selegiline: antidepressant-like activity in rats Pharmacol Biochem Behav 63 1999 501 506
56. J.D. Amsterdam A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder J Clin Psychiatr 64 2003 208 214
57. E. Head, and N.W. Milgram Changes in spontaneous behavior in the dog following oral administration of l-deprenyl Pharmacol Biochem Behav 43 1992 749 757
58. J. Timar, Z. Gyarmati, L. Barna, and B. Knoll Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats Physiol Behav 60 1996 581 587
59. C. Okuda, D.S. Segal, and R. Kuczenski Deprenyl alters behavior and caudate dopamine through an amphetamine-like action Pharmacol Biochem Behav 43 1992 1075 1080